|06/26/18||Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases|
|SOUTH SAN FRANCISCO, Calif., June 26, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects. Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials. Preclinical studies show that R835 inhibits both the IRAK1 and IRAK4 signaling pathwa... |
|06/20/18||Rigel Announces Poster Presentations at FOCIS Annual Meeting|
|SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting in San Francisco, June 20-23, 2018.
Poster presentation details:
Thursday, June 21st, 6:25–7:30pm PDT
Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor, in Adult Persistent/Chronic Immune Thr... |
|06/12/18||Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA|
|SOUTH SAN FRANCISCO, Calif., June 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at the 23rd Congress of the European Hematology Association (EHA) being held June 14-17, 2018, in Stockholm, Sweden.
Title: FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF ... |